Recent studies have elucidated the presence of a CD133+/CD24+ cell subpopulation in ccRCC, which promotes angiogenesis within the TME and contributes to resistance against multitarget tyrosine kinase inhibitors, leading to tumor progression and poor prognosis. This evidence concerns the gene PROM1 and nonpapillary renal cell carcinoma.